Lincoln Pharma Q2 revenue rises 17.8%, earnings margin narrows

Ebitda Margin CompressionResults View source PDF Explain this filing

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.0%Reaction day

₹558.05

prior close

₹512.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-9.6% vs market

Pharmaceuticals peers, median of 171sector+0.4%-9.3% vs sector

On the reaction day the stock moved 9.6 pts less than Nifty Microcap 250 and 9.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.8

15m

+3.3

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.0+0.7-9.6+0.4-9.3

Next day

-10.8pendingpending-0.6-10.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lincoln Pharmaceuticals reported unaudited Q2 results to September 30, 2026. Revenue rose 17.1% year on year to Rs 191.35 crore and total income rose 17.8% to Rs 200.88 crore. Profit after tax was Rs 20.43 crore and earnings per share was Rs 10.20. Earnings before interest, tax, depreciation and amortization rose only 1.7% to Rs 33.22 crore, narrowing the margin. For six months, profit after tax rose 18.9% to Rs 56.66 crore. The company remains net debt free.

Likely market impact

Growth and a net debt-free balance sheet support the stock, but Q2 cash earnings rose only 1.7% against 17.8% revenue growth.